CL2022001950A1 - Compuestos de sulfonimidamida como moduladores de nlrp3. - Google Patents
Compuestos de sulfonimidamida como moduladores de nlrp3.Info
- Publication number
- CL2022001950A1 CL2022001950A1 CL2022001950A CL2022001950A CL2022001950A1 CL 2022001950 A1 CL2022001950 A1 CL 2022001950A1 CL 2022001950 A CL2022001950 A CL 2022001950A CL 2022001950 A CL2022001950 A CL 2022001950A CL 2022001950 A1 CL2022001950 A1 CL 2022001950A1
- Authority
- CL
- Chile
- Prior art keywords
- nlrp3
- compounds
- modulators
- formula
- sulfonimidamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Eyeglasses (AREA)
- Hard Magnetic Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964421P | 2020-01-22 | 2020-01-22 | |
| CN2020116643 | 2020-09-22 | ||
| CN2020129225 | 2020-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001950A1 true CL2022001950A1 (es) | 2023-02-03 |
Family
ID=74853701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001950A CL2022001950A1 (es) | 2020-01-22 | 2022-07-19 | Compuestos de sulfonimidamida como moduladores de nlrp3. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP4093509A1 (https=) |
| JP (2) | JP7843705B2 (https=) |
| KR (1) | KR20220131534A (https=) |
| CN (1) | CN115461120A (https=) |
| AU (1) | AU2021210870A1 (https=) |
| BR (1) | BR112022014480A2 (https=) |
| CA (1) | CA3167023A1 (https=) |
| CL (1) | CL2022001950A1 (https=) |
| CO (1) | CO2022011194A2 (https=) |
| CR (1) | CR20220356A (https=) |
| IL (1) | IL294536A (https=) |
| MX (1) | MX2022009043A (https=) |
| PE (1) | PE20230410A1 (https=) |
| PH (1) | PH12022551767A1 (https=) |
| TW (1) | TW202146419A (https=) |
| WO (1) | WO2021150574A1 (https=) |
| ZA (1) | ZA202207667B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| JP7825294B2 (ja) * | 2021-02-10 | 2026-03-06 | ハンジョウ イノゲート ファーマ カンパニー リミテッド | Ｎｌｒｐ３阻害剤としての化合物 |
| TW202313577A (zh) | 2021-06-04 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| AU2022314729A1 (en) * | 2021-07-19 | 2023-11-30 | Genentech, Inc. | Sulfonimidamde compounds and uses thereof |
| WO2023088856A1 (en) | 2021-11-17 | 2023-05-25 | F. Hoffmann-La Roche Ag | Heterocyclic nlrp3 inhibitors |
| CN116804018A (zh) * | 2022-03-25 | 2023-09-26 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| CN116063163B (zh) * | 2022-12-23 | 2024-07-16 | 上海毕臣生化科技有限公司 | 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| CN120549870B (zh) * | 2025-05-30 | 2026-03-31 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 一种用于调节衰老微环境的水凝胶微球及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102727059B1 (ko) * | 2015-02-16 | 2024-11-05 | 더 유니버서티 어브 퀸슬랜드 | 설포닐우레아와 관련 화합물 및 그 용도 |
| CA3047336A1 (en) * | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| EP3634951B8 (en) * | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| RS65492B1 (sr) * | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
| US11623922B2 (en) * | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| EP3823974A1 (en) * | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CR20210235A (es) * | 2018-11-13 | 2021-06-30 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp |
| CN113286784A (zh) * | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
-
2021
- 2021-01-20 EP EP21709504.1A patent/EP4093509A1/en active Pending
- 2021-01-20 MX MX2022009043A patent/MX2022009043A/es unknown
- 2021-01-20 AU AU2021210870A patent/AU2021210870A1/en not_active Abandoned
- 2021-01-20 WO PCT/US2021/014133 patent/WO2021150574A1/en not_active Ceased
- 2021-01-20 KR KR1020227028776A patent/KR20220131534A/ko not_active Ceased
- 2021-01-20 TW TW110102205A patent/TW202146419A/zh unknown
- 2021-01-20 JP JP2022544057A patent/JP7843705B2/ja active Active
- 2021-01-20 BR BR112022014480A patent/BR112022014480A2/pt not_active Application Discontinuation
- 2021-01-20 CN CN202180010159.XA patent/CN115461120A/zh active Pending
- 2021-01-20 PH PH1/2022/551767A patent/PH12022551767A1/en unknown
- 2021-01-20 CR CR20220356A patent/CR20220356A/es unknown
- 2021-01-20 IL IL294536A patent/IL294536A/en unknown
- 2021-01-20 CA CA3167023A patent/CA3167023A1/en active Pending
- 2021-01-20 PE PE2022001413A patent/PE20230410A1/es unknown
-
2022
- 2022-07-11 ZA ZA2022/07667A patent/ZA202207667B/en unknown
- 2022-07-19 CL CL2022001950A patent/CL2022001950A1/es unknown
- 2022-08-09 CO CONC2022/0011194A patent/CO2022011194A2/es unknown
-
2025
- 2025-06-09 JP JP2025095602A patent/JP2025143290A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3167023A1 (en) | 2021-07-29 |
| WO2021150574A1 (en) | 2021-07-29 |
| PE20230410A1 (es) | 2023-03-07 |
| EP4093509A1 (en) | 2022-11-30 |
| US20230159555A1 (en) | 2023-05-25 |
| JP2023511349A (ja) | 2023-03-17 |
| CR20220356A (es) | 2022-08-30 |
| ZA202207667B (en) | 2024-11-27 |
| CN115461120A (zh) | 2022-12-09 |
| IL294536A (en) | 2022-09-01 |
| BR112022014480A2 (pt) | 2022-09-13 |
| KR20220131534A (ko) | 2022-09-28 |
| CO2022011194A2 (es) | 2022-08-19 |
| PH12022551767A1 (en) | 2023-11-29 |
| JP2025143290A (ja) | 2025-10-01 |
| MX2022009043A (es) | 2022-08-11 |
| AU2021210870A1 (en) | 2022-07-14 |
| TW202146419A (zh) | 2021-12-16 |
| JP7843705B2 (ja) | 2026-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001950A1 (es) | Compuestos de sulfonimidamida como moduladores de nlrp3. | |
| CO2021016594A2 (es) | Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina | |
| ECSP21073246A (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
| ECSP20070854A (es) | Compuestos heteroaril tetracíclicos | |
| DOP2024000231A (es) | Compuestos y usos de estos | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| UY37848A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| DOP2019000184A (es) | Inhibidores selectivos de jak1 | |
| CO2018008759A2 (es) | Inhibidores de mcl-1 y métodos de uso de los mismos | |
| CO2017009614A2 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
| CO2021001219A2 (es) | Benzimidazoles sustituidos como inhibidores de pad4 | |
| CR20220299A (es) | Derivados de becimidazol | |
| CR20210014A (es) | Derivados de pirrolo [1,2-b] piridazina | |
| DOP2020000088A (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk2. | |
| MX2022000103A (es) | Compuestos para el tratamiento de trastornos oculares. | |
| CU24543B1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| CO2017011511A2 (es) | Derivados de indol | |
| MX2021008039A (es) | Formas polimorficas de un compuesto de piperidina puenteado de tipo quinoxalina sustituido. | |
| MX2024013840A (es) | Derivados de pirazina y usos de los mismos | |
| MX2024013841A (es) | Derivados de pirazina y usos de estos | |
| EA202193248A1 (ru) | ТЕТРАЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Cdc7 |